Emcure Pharmaceuticals Ltd
Incorporated in 1981, Emcure Pharmaceuticals Limited is an Indian company that develops, manufactures, and markets a wide range of pharmaceutical products globally across several major therapeutic areas.[1]
- Market Cap ₹ 24,510 Cr.
- Current Price ₹ 1,296
- High / Low ₹ 1,409 / 1,260
- Stock P/E 48.7
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 18.6 %
- ROE 18.5 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 7.14% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 4,717 | 5,049 | 5,033 | 5,855 | 5,986 | 6,658 | |
| 3,968 | 4,340 | 3,817 | 4,525 | 4,804 | 5,429 | |
| Operating Profit | 749 | 708 | 1,216 | 1,330 | 1,182 | 1,230 |
| OPM % | 16% | 14% | 24% | 23% | 20% | 18% |
| 72 | -25 | -159 | 63 | 39 | 47 | |
| Interest | 223 | 257 | 155 | 176 | 214 | 237 |
| Depreciation | 267 | 321 | 250 | 245 | 260 | 312 |
| Profit before tax | 331 | 105 | 652 | 973 | 747 | 727 |
| Tax % | 37% | 4% | 36% | 28% | 25% | 27% |
| 209 | 101 | 419 | 703 | 562 | 528 | |
| EPS in Rs | 10.79 | 4.62 | 23.15 | 36.62 | 29.42 | 27.50 |
| Dividend Payout % | 32% | 0% | 4% | 8% | 7% | 11% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 10% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 6% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 24% |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 181 | 181 | 181 | 181 | 181 | 181 |
| Reserves | 1,654 | 1,731 | 2,092 | 1,807 | 2,320 | 2,771 |
| 2,128 | 2,327 | 2,310 | 2,217 | 2,334 | 2,335 | |
| 1,613 | 1,721 | 2,184 | 1,816 | 1,798 | 2,422 | |
| Total Liabilities | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 |
| 2,247 | 2,382 | 2,188 | 2,044 | 2,147 | 3,125 | |
| CWIP | 581 | 485 | 302 | 320 | 411 | 159 |
| Investments | 0 | 0 | 0 | 25 | 25 | 318 |
| 2,749 | 3,093 | 4,278 | 3,632 | 4,050 | 4,108 | |
| Total Assets | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 444 | 500 | 704 | 768 | 747 | 1,097 | |
| -409 | -168 | -256 | -574 | -468 | -715 | |
| -735 | -301 | -189 | -152 | -145 | -164 | |
| Net Cash Flow | -700 | 32 | 259 | 42 | 134 | 219 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 75 | 83 | 107 | 82 | 101 | 102 |
| Inventory Days | 234 | 211 | 293 | 237 | 223 | 225 |
| Days Payable | 142 | 133 | 188 | 184 | 175 | 193 |
| Cash Conversion Cycle | 167 | 161 | 212 | 135 | 148 | 134 |
| Working Capital Days | 69 | 67 | 75 | 96 | 112 | 103 |
| ROCE % | 11% | 22% | 26% | 21% | 19% |
Documents
Announcements
- Press Release Titled 'Emcure Pharmaceuticals Strengthens Its Commitment To Energy Conservation, Signs PPA With Sunsure Energy For Solar Power' 25 Jul
-
Announcement under Regulation 30 (LODR)-Acquisition
25 Jul - Emcure Pharmaceuticals Limited ("Emcure"), together with its subsidiary, Gennova Biopharmaceuticals Limited ("Gennova"), has entered into a Share Subscription and Shareholders'' Agreement dated July 25, 2024. …
-
Disclosure Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015
24 Jul - Details of Key Managerial Personnel severally authorized pursuant to Regulation 30(5) of SEBI (LODR) Regulations, 2015, for the purpose of determining the materiality of an …
- Closure of Trading Window 10 Jul
- Listing of Equity Shares of Emcure Pharmaceuticals Ltd 10 Jul
Market Leadership[1] Emcure was ranked 13th in domestic sales and ranked fourth in its covered markets for FY24. It was the largest pharmaceutical company in the gynecology and HIV antivirals therapeutic areas in terms of domestic sales for MAT FY2024.